There is 1 paper on incident clinical peripheral artery disease in aging research: 1 observational study in people.
1 paper studies it4 findings
See all 1 papers on incident clinical peripheral artery disease
“Five biomarkers, sCD14, hsCRP, WBC, sTNFR1, and sIL2Rα, were associated with incident PAD.”
- Humans1
Associations
4Soluble IL-2 receptor alpha
upin humans1
1 study
Soluble IL-2 receptor alpha
upin humans1
Soluble IL-2 receptor alpha is associated with incident clinical peripheral artery disease in humans (adjusted for demographic, behavioral, and clinical risk factors).
“Five biomarkers, sCD14, hsCRP, WBC, sTNFR1, and sIL2Rα, were associated with incident PAD.”
Humansadjusted for demographic, behavioral, and clinical risk factorsmedian follow-up 13.9 yearsn = 5,061
AHA Scientific Sessions 2025 abstract
Soluble TNFR1
upin humans1
1 study
Soluble TNFR1
upin humans1
Soluble TNFR1 is associated with incident clinical peripheral artery disease in humans (adjusted for demographic, behavioral, and clinical risk factors).
“Five biomarkers, sCD14, hsCRP, WBC, sTNFR1, and sIL2Rα, were associated with incident PAD.”
Humansadjusted for demographic, behavioral, and clinical risk factorsmedian follow-up 13.9 yearsn = 5,061
AHA Scientific Sessions 2025 abstract
C-reactive protein
upin humans1
1 study
C-reactive protein
upin humans1
C-reactive protein is associated with incident clinical peripheral artery disease in humans (adjusted for demographic, behavioral, and clinical risk factors).
“Five biomarkers, sCD14, hsCRP, WBC, sTNFR1, and sIL2Rα, were associated with incident PAD.”
Humansadjusted for demographic, behavioral, and clinical risk factorsmedian follow-up 13.9 yearsn = 5,061
AHA Scientific Sessions 2025 abstract
Soluble CD14
upin humans1
1 study
Soluble CD14
upin humans1
Soluble CD14 is associated with incident clinical peripheral artery disease in humans (adjusted for demographic, behavioral, and clinical risk factors).
“Five biomarkers, sCD14, hsCRP, WBC, sTNFR1, and sIL2Rα, were associated with incident PAD.”
Humansadjusted for demographic, behavioral, and clinical risk factorsmedian follow-up 13.9 yearsn = 5,061
AHA Scientific Sessions 2025 abstract